Aug 15, 2025
The price patients will pay for the PFS

After a recent survey we conducted, it is clear most clinicians agreed skin substitutes are highly effective and essential, warning that the proposed rates would reduce patient access, hinder innovation, and threaten the viability of many practices. Read the blog to learn more about our findings.

The entire wound care community has expressed serious concern about CMS’s proposed changes to skin substitute coverage and reimbursement, including the proposed 2025 Physician Fee Schedule (PFS). To gauge the response of clinicians to CMS’ proposals, we recently conducted a survey of mobile and office based wound care specialists. Additional surveys are in process to gather more information about this critically important subject.

Of the clinicians responded to our survey, the large majority had multiple years of experience treating Medicare patients with chronic wounds.

Likewise, the majority of responding clinicians were seeing 10 or more Medicare wound care patients each week, with 6 clinicians seeing 30 patients or more on average.

The responding clinicians were virtually unanimous in their opinion that skin substitutes were “very effective” in the treatment of their patients.

The vast majority also viewed skin substitutes as very important to the clinical treatment of their wound patients.

These clinicians as a group were very concerned about the impacts of the proposed skin substitute reimbursement reductions, with 87% reporting that the proposed changes would have either a “critical impact” or a “serious impact” on their practices and their ability to treat Medicare wound patients.

When asked about specific possible reimbursement rates, more than 60% responded that at a reimbursement rate of $500 per sq centimeter or below, they would be forced to start reducing their use of skin substitutes for Medicare patients due to financial constraints. Many also responded that they could be forced to change their practice and stop seeing chronic wound patients in their current business model altogether. This would obviously lead to negative long-term impacts on patients, but there are even more challenges anticipated should the currently proposed $125.38 price become effective.

There is also the problem with low application code reimbursement pressuring the manufacturers to discount in an unsustainable manner. Specific to application fees, the proposed PFS professes to achieve reimbursement parity among providers in all places of service but fails to address that the physician portion of the application code in the HOPD place of service is now and will remain about $780.00 but is only about $150 in the private office and mobile settings. The implications of this disparity are that independent physicians will remain in a position where they could be forced to choose the lowest priced product available regardless of scientific or clinical evidence, and as a consequence, innovation would disappear from the market. Longer term, the producers will disappear, leaving the lowest priced and likely the least effective products in an oligopoly which will again lead to price escalation problems. Raising the physician application fee to parity with the HOPD would significantly mitigate this issue. More than 80% of survey respondents indicated the current physician fee for skin substitute application is too low and should be raised.

Wound care is a challenging field of practice with limited reimbursement and growing numbers of patients requiring treatment. Reductions in the availability of treatments and providers would seriously impact patient access. CMS should carefully consider the collateral damage its proposed policies might cause before settling on an appropriate set of reimbursement rates.

More News & Updates

Stay Up-To-Date With
Venture Medical

Aug 11, 2025

Skin Substitutes: An Inconvenient Truth

Proposed Medicare Cuts To Skin Substitutes Could Force Wound Care Clinicians Out, Putting Thousands of Patients at Risk.

Aug 4, 2025

The Case For Mobile Wound Care: An Essential Component Of Chronic Wound Management

Mobile wound care is a critical yet often misunderstood part of chronic wound management, providing advanced treatment to patients who can't easily access traditional care. Far from being a fringe service, it’s a large and growing field—with nearly 30,000 clinicians billing for mobile wound services in 2023 alone—and plays a key role in addressing the rising burden of chronic wounds, especially in nursing homes. As wound severity increases, staffing shortages persist, and the population ages, mobile providers are filling care gaps through high-volume, high-quality services and innovative tools like AI-assisted telehealth and near-infrared spectroscopy. To ensure better outcomes and lower healthcare costs, policymakers and payers must recognize mobile wound care as an essential, professional solution—not a peripheral one.

Jul 30, 2025
John Schroeder
John Schroeder

Venture Position on CMS and MAC Skin Substitute Proposals

Venture Medical, LCC is sharing our position on the CY2026 Medicare Physician Fee Schedule and our future recommendations.

Jul 23, 2025
John Schroeder & Howard Walthall
John Schroeder & Howard Walthall

How CMS Fudged the Math:

If we want reimbursement systems that reflect real-world care and outcomes, we need to speak up. The comment period is now open. Read the full breakdown from John Schroeder and Howard Walthall to learn more about how you can join the call for fair, evidence-based reimbursement.

Jul 11, 2025

The 2026 OPPS and PFS Rules: A Defining Moment for CAMPS Payment Reform

Venture Medical, a leader in wound care solutions, stands at the forefront of advocating for patient access and innovation in response to the 2026 Hospital Outpatient Prospective Payment System (OPPS) proposed rule.

Jul 7, 2025
Michael Schroeder
Michael Schroeder

Venture Medical Leads Investment in Plasmacure to Advance Breakthrough Cold Plasma Technology for Chronic Wound Healing

Venture Medical announces the closing of a strategic investment in Plasmacure B.V., the Dutch MedTech innovator behind PLASOMA, an award-winning cold plasma therapy for complex wound healing.

Jun 12, 2025
John Schroeder
John Schroeder

Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio

Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio

May 1, 2025

Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market

Apr 4, 2025

The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination

Mar 11, 2025

Open Wound Research and Venture Medical Announce Collaboration to Advance Pressure Ulcer Research